Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women

16 novembre 2026 mis à jour par: Stephanie M Gorka, PhD, Ohio State University

The goal of this clinical trial is to determine whether women who engage in heavy drinking with a history of sexual assault (SA) victimization show heightened baseline reactivity to uncertain threat (U-threat), whether alcohol reduces this reactivity and related anxiety, and how these processes link to real-world drinking behavior. The main questions it aims to answer are:

  • Test whether heavy drinking women with a history of SA display exaggerated baseline reactivity to U-threat.
  • In the lab, test whether alcohol intoxication is associated with decreases in reactivity to U-threat and subjective anxiety, particularly in heavy drinking women with a history of SA.
  • In the real-world, test associations between SA victimization, reactivity to U-threat, alcohol consumption, and anxiolytic relief.

Participants will:

  • Complete a screening and orientation session
  • Complete two experimental lab sessions that will include intravenous (IV) administration of either 80mg% alcohol or placebo (saline), order counterbalanced
  • Complete daily ecological momentary assessments (EMA) surveys for 21 days
  • Wear a transdermal alcohol wrist biosensor (BACTrack Skyn) for 21-days

Aperçu de l'étude

Statut

Recrutement

Type d'étude

Interventionnel

Inscription (Estimé)

220

Phase

  • Première phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Ohio
      • Columbus, Ohio, États-Unis, 43210
        • Recrutement
        • Ohio State University
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

21 ans à 29 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

General Inclusion Criteria for All Participants:

  • Biological female
  • 21-29 years old
  • At least a high school education
  • Fluency in English
  • Heavy drinker as defined as 8 or more alcoholic drinks per week and at least two binge episodes (4 or more drinks for in a 2-hour period) in the past month

Additional Inclusion Criteria for Heavy Drinkers with History of Sexual Assault (HD+SA) Group:

- Self-reported experience of sexual assault victimization after age 14.

Additional Inclusion Criteria for Heavy Drinkers without History of Sexual Assault (HD-SA) Group:

- No exposure to lifetime DSM-5 Criterion A traumatic stressor. Participants will not be excluded for accidents, injuries, or witnessing community violence to ensure the sample is representative.

Exclusion Criteria for All Participants:

  • Any serious medical problems (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, and gastrointestinal disorders)
  • Body weight < 110 or > 210 lbs
  • Current medical or psychiatric condition requiring medication for which alcohol consumption is contraindicated
  • Substance use disorder other than mild and moderate alcohol use disorder
  • Positive urine screen for drugs other than cannabis
  • Currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors
  • Pregnancy, nursing, or planning to become pregnant in the next 3 months
  • Report smoking more than 5 cigarettes (or electronic equivalent) per day
  • Lifetime history of psychosis.

Additional Exclusion Criteria for HD+SA Group:

- Report a first onset SA within the past 30 days

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Autre: Heavy Drinking with a History of Sexual Assault Victimization (HD+SA)

Participants in this group will be required to be biological females between the ages of 21-29 who engage in heavy drinking with a history of sexual assault victimization after age 14.

Participants receive placebo (saline) intravenously.

Participants will receive 80 mg% intravenous alcohol.

Autre: Heavy Drinking without a History of Sexual Assault Victimization (HD-SA)

Participants in this group will be required to be biological females between the ages of 21-29 who engage in heavy drinking either without a history of sexual assault victimization after age 14.

Participants receive placebo (saline) intravenously.

Participants will receive 80 mg% intravenous alcohol.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Startle eyeblink potentiation during the threat task
Délai: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)

Startle eyeblink potentiation will be collected during the NPU threat task that is administered at all three lab sessions. Startle is a cross-species index of aversive reactivity.

Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
Subjective affective response to alcohol in the lab
Délai: At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

Participants will complete the Profile of Mood States (POMS) throughout the placebo and alcohol administration protocols. The Profile of Mood States Anxiety subscale consists of 9 items, with each item rated from 0 (not at all) to 4 (extremely), resulting in a total score ranging from 0 to 36. Higher scores indicate greater subjective anxiety, while lower scores indicate less subjective anxiety. The Anxiety subscale will serve as the primary measure of subjective anxiety and will be compared between the placebo and alcohol sessions.

At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
Subjective effects of alcohol in the lab
Délai: At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

Participants will rate the degree to which they 'feel', 'like', and 'want more' of the infused substance on a visual analogue scale ranging from 0 ('not at all') to 100 ('extremely'). The 'like' and 'want more' scales will serve as the primary measures of drug liking and drug wanting, respectively.

At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
Ecological momentary assessment (EMA) of affective response to alcohol in the real world
Délai: Assessed daily for 21-days

Up to five times per day, participants will complete ecological momentary assessments (EMA) of their current anxiety, distress, and other mood states. Participants will rate each emotion on a 0-5 scale, where 0 = not at all and 5 = extremely. Affect will be assessed during periods of sobriety and intoxication.

Assessed daily for 21-days
Transdermal alcohol concentration (TAC)
Délai: Assessed daily for 21-days

Participants' TAC will provide an objective estimate of alcohol consumption.

Assessed daily for 21-days

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 août 2031

Achèvement de l'étude (Estimé)

1 août 2031

Dates d'inscription aux études

Première soumission

16 septembre 2026

Première soumission répondant aux critères de contrôle qualité

19 octobre 2026

Première publication (Réel)

26 octobre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 2024H0264
  • 1R01AA032115-01A1 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified data, including startle eyeblink and behavior, from this project will be submitted to the The National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAADA) at the subject level along with appropriate supporting documentation to enable efficient use of the data by the research community. We will follow instructions as discussed in the NDA Data Sharing Terms and Conditions.

Délai de partage IPD

The data will be submitted biannually.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner